Overview

A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women

Status:
Completed
Trial end date:
2007-07-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of romosozumab following single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen